



Introduction to Pharmacophore Searching Using CSD-CrossMiner

CCDC Virtual Workshop

November 2024



Learning outcomes

- ❑ An understanding of the [pharmacophore concept](#).
- ❑ [Familiarity with](#) the [CSD-CrossMiner](#) interface and how it can be used in your research.
- ❑ How to [perform pharmacophore searches](#) biologically relevant subsets of the [CSD](#) and [PDB](#).
- ❑ How to set up an [interactive pharmacophore query](#) and [save](#) the [results](#).
- ❑ How to [analyse](#) and [interact](#) with your results.

We will make the
recording available to you
in the next few days.

Agenda

- *Show One*: Intro and CSD and CSD-CrossMiner overview
- *Show One*: PDB overview
- *Show One*: CSD-CrossMiner explained and demonstration
- *Try One*: Hands-on example
- *Explore More*: Case-studies of CSD-CrossMiner
- *Explore More*: Quiz and Summary
- *Extra time*: More time for hands on and Q&A

Special Guest




Deborah Harrus

PDBe Archive
Project Leader



CCDC

The Cambridge Structural Database



- Every published structure
 - Inc. ASAP & early view
 - *CSD Communications*
 - Patents
 - University repositories
 - Thesis
- Every entry enriched and annotated by experts
- Discoverability of data and knowledge
- Sustainable for over 59 years
- A trusted CoreTrustSeal repository



Certified as Trustworthy
by CoreTrustSeal

Small molecules, big impact


200 top drugs by retail sales in 2023

Small molecule structure in the CSD


- Open-up new biological and therapeutic opportunities
- Compete against emergent modalities for rare diseases
- Are used to target RNA*

Small molecule structure CSD entry pending

Biological structure in the PDB



FDA novel drug approvals 2023



CCDC

Small Molecule Drugs Continue to be Crucial in Advancing Healthcare with 34 New Approvals in 2023 Compared to 21 in 2022

The Food and Drug Administration (FDA) approved 55 new drugs in 2023, an increase of nearly 50% from the 37 approvals in 2022, the second highest number in the past 30 years [1].

34 out of the 55 approved new drugs are small molecules, representing 62% of the total. The growing number of small molecules from the previous years, corresponding to the 56% in 2021 (28 out of 50) and 57% in 2022 (21 out of 37), shows how this class of drugs continues to be crucial in advancing health care.




CCDC

Adapted from poster compiled and produced by the Njardarson Group (The University of Arizona)





*Nature Reviews Drug Discovery 20, 85-90 (2021)

Using integrated structural databases



Connecting chemistry and biology




3p4w > DSF



The CSD Portfolio

CSDCore.

*Search, visualise, analyse and communicate structural data
Insights into molecular and crystal shape and interactions*



CSDEnterprise.


CSDDiscovery.

Design of new molecules




CSDMaterials.

Assessment of solid form stability and properties




CSDParticle.

Anticipate particle properties and behaviour





CSDTheory.

Generate solid form landscapes



CSDCommunity.

*Deposit, publish, access and visualise structural data
Free functionality to share and learn from structures*



Medicinal & Computational Chemists ♦ Crystallographers & Structural Biologists ♦ Solid Form & Crystallisation Scientists ♦ Functional Materials Scientists ♦ Educators ♦ Industry and Academia

CCDC

CSD-CrossMiner - origin

- Developed in collaboration with **Roche**.

"We exemplify the utility of the approach by **showing applications relevant to real-world drug discovery** projects, including the identification of novel fragments for a specific protein environment or scaffold hopping."

"We believe that CSD-CrossMiner **closes an important gap in mining structural data** and will allow users to extract more value from the growing number of available crystal structures."



Interactive and Versatile Navigation of Structural Databases

Oliver Korb¹, Bernd Kuhn², Jérôme Hert², Neil Taylor³, Jason Cole¹, Colin Groom¹, Martin Stahl²


Affiliations + expand

PMID: 26745458 DOI: 10.1021/acs.jmedchem.5b01756

Abstract


We present CSD-CrossMiner, a novel tool for pharmacophore-based searches in crystal structure databases. Intuitive pharmacophore queries describing, among others, protein-ligand interaction patterns, ligand scaffolds, or protein environments can be built and modified interactively. Matching crystal structures are overlaid onto the query and visualized as soon as they are available, enabling

the rese
showing
novel fra
search p
molecul
further e
importa
number




CSD-CrossMiner: Why you may need it

You have a known ligand and want to find a new one with better properties but the same target interactions.




You have a known target with a known binding pocket and want to find compounds which can bind to the pocket.



CSD-CrossMiner - applications

- Advance **hit-to-lead**
- Lead **optimisation**
- Find **scaffold hops** to improve pharmacokinetics



- Identify **off-target** effects
- Understand which **modifications** are tolerated in the binding site
- Generate **new ideas** in drug discovery projects

Pharmacophore search applications

- **Design novel motifs** that mimic established ligands to improve physicochemical properties or solve patent issues.
- **Scaffold-hopping**: retrieve a diversity of ligand topologies that can be used as scaffolds for lead optimization.
- Look at chemistries that interact with **unexplored parts** of the binding site to improve binding properties of a ligand.


CSD-CrossMiner specific

- Determine **common protein binding sites** to predict selectivity.
- Shed light into **cross-pharmacology** between protein targets.
- Determine **structural motifs** that bind in **similar environments** to find insights for drug design and optimization.


CSD-CrossMiner




- Tool for building pharmacophore queries.
- Tool for searching structural databases by pharmacophore.
- Simultaneously search the PDB, CSD and your in-house database.
- Designed for speed – modify hypotheses on the fly.
- Structures are annotated for easy filtering of hits.




CSD-CrossMiner - workflow



1. **Observe** the protein-ligand complex.




2. **Define** the ligand and protein pharmacophore, and any constraints



3. See **matching hits** overlaid – **explore** each in the browser.

HBD – Hydrogen Bond Donor; HBA – Hydrogen Bond Acceptor; HA – Heavy Atom;
RA – Ring Aromatic; ExV – Exit Vector

CSD-CrossMiner: Feature Databases



- **Simultaneously mine data sources.**
- Public and proprietary.
- Find matches by pharmacophore.
- These are **annotated versions** of the original databases, to include pharmacophore features information.

Feature Databases			
	database	size	
☒	pdb_crossminer	402583	
☒	nucleic_acid_crossminer	7554	
☒	csd545_crossminer	502124	
☒	Mar24_ASER	7492	

⚡ The CSD is updated regularly!

- Building of in-house databases and their integration into CSD-CrossMiner is possible.

We will make the
recording available to you
in the next few days.

Agenda


- *Show One*: Intro and CSD and CSD-CrossMiner overview
- *Show One*: PDB overview
- *Show One*: CSD-CrossMiner explained and demonstration
- *Try One*: Hands-on example
- *Explore More*: Case-studies of CSD-CrossMiner
- *Explore More*: Quiz and Summary
- *Extra time*: More time for hands on and Q&A

Special Guest



Deborah Harrus

PDBe Archive Project
Leader



We will make the
recording available to you
in the next few days.

Agenda

- *Show One*: Intro and CSD and CSD-CrossMiner overview
- *Show One*: PDB overview
- *Show One*: CSD-CrossMiner explained and demonstration
- *Try One*: Hands-on example
- *Explore More*: Case-studies of CSD-CrossMiner
- *Explore More*: Quiz and Summary
- *Extra time*: More time for hands on and Q&A

Show One: The basics – A pharmacophore

“A **pharmacophore** is the **ensemble** of **steric** and **electronic features** that is **necessary** to ensure the optimal supramolecular **interaction** with a specific **biological target** structure and to trigger (or block) its **biological response**.”

C.G.Wermuth, C.R.Ganellin, P.Lindberg, L.A. Mitscher (1998). "Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)" DOI: [10.1351/pac199870051129](https://doi.org/10.1351/pac199870051129)




A concept is **originated by Paul Ehrlich (1909)** and developed by Schueler in his book “*Chemobiodynamics and Drug Design*” (1960)


Osman F. Güner and J. Phillip Bowen (2014). “Setting the Record Straight: The Origin of the Pharmacophore Concept” DOI: [10.1021/ci5000533](https://doi.org/10.1021/ci5000533)

Pharmacophore feature

Pharmacophore feature – an atom or a group of atoms with **sterical** or **electrostatic properties essential** for the **activity to a target protein**.




Pharmacophore feature



CCDC

Pharmacophore features in CSD-CrossMiner



acceptor	ALA
acceptor_projected	ARG
donor_ch_projected	ASN
donor_projected	ASP
heavy_atom	CYS
hydrophobe	GLN
ring	GLU
ring_non_planar	GLY
ring_planar_projected	HIS
purine	ILE
pyrimidine	LEU
adenine	LYS
cytosine	MET
guanine	PHE
thymine	PRO
uracil	SER
deoxyribose	THR
ribose	TRP
exit_vector	TYR
halogen	VAL
bromine	excluded_volume
chlorine	annotation_filter
fluorine	substructure_filter
metal	
water	



Pharmacophore features in CrossMiner


A pharmacophore point is a feature that has been selected to be a pharmacophore because its presence is necessary.

- Single point, acceptor
- Between two points, donor_projected



CSD-CrossMiner - features

- **Customise** feature definitions
 - Explore new chemistry
 - Improve search granularity
- **Excluded** volume
 - Cut noise by removing occupational volume




Pharmacophore query

Pharmacophore query (or just pharmacophore) is an ensemble of steric and electronic features that characterise a protein and/or a small molecule.

- What interactions are present and most common in protein-ligand complexes you have?
- Which pharmacophore features are the most common among known ligands binding to a same target?
- Are there any unsatisfied interactions in the target's pocket?
- Are there any interactions you'd like to eliminate?



Pharmacophore query




Run the search

2HZ1 - CSD-CrossMiner

File Edit Display Feature Database Help

Style: Wireframe Colour: by Element Picking Mode:

Show: ☒ reference ☒ hits ☒ constraints ☐ features ☒ pharmacophore ☒ pharm. labels ☐ hydrogens Edit: Search:



Feature Databases

database	size
☒ pdb_crossminer	326877
☒ nucleic_acid_crossminer	6041
☒ csd542_crossminer	428847


Results Hitlist

☒ 1st in cluster Settings... Tanimoto: 0.70 Number of hits: 100 Show all


mark	identifier	cluster	rmsd	diagram	chain	deposition
------	------------	---------	------	---------	-------	------------

#hits: 0/10000


CSD-CrossMiner - workflow



1. Observe the protein-ligand complex.




2. Define the ligand and protein pharmacophore, and any constraints



3. See matching hits overlaid – explore each in the browser.

HBD – Hydrogen Bond Donor; HBA – Hydrogen Bond Acceptor; HA – Heavy Atom;
RA – Ring Aromatic; ExV – Exit Vector

Show One: CSD-CrossMiner Demonstration



In this demo we will see how to:

- Navigate CSD-CrossMiner
- Perform a Pharmacophore Search

This is a good time to open CSD-CrossMiner!

The screenshot shows the CSD-CrossMiner software interface. The main window displays a 3D molecular model of a complex organic molecule with green and red spheres representing atoms and bonds. The interface includes a menu bar (File, Edit, Display, Feature Database, Export, Help) and a toolbar with various icons for file operations and search. A search bar is located on the right side of the toolbar. The interface is divided into several panels:

- File menus and tool bars**: Located at the top of the window.
- Start/Pause search**: A button located on the right side of the toolbar.
- 3D visualiser**: The main area displaying the 3D molecular model.
- Feature Databases**: A panel on the right showing a list of databases (pdb_crossminer, nucleic_acid_crossminer, csd4545_crossminer) with their respective sizes.
- Results Hitlists**: A panel on the right showing a list of search results (CURRIS_1, BEZVEL_1, BEZVAH_1) with their respective cluster sizes and RMSD values.
- Progress bar**: A bar at the bottom of the Results Hitlists panel showing the progress of the search.
- Pharmacophore Features**: A panel at the bottom right showing a list of pharmacophore features (acceptor, acceptor_projected, donor_ch_projected, donor_projected, heavy_atom, hydrophobe, hydrophobe_1, ring, ring_non_planar, ring_planar_projected) with their respective tolerance radii and checkboxes for showing in reference and pharmacophore.

Try One: Hands-on exercise

We will make the recording available to you in the next few days.

It's your turn!

- Try the **case study** from the handout.
- Your tutors are on hand to help you!
- To ask questions during this time **type a message in the chat box**.
- **If you finish early**, ask us for more challenging examples.

Creating a Pharmacophore Query from a Reference Molecule & Scaffold Hopping in CSD-CrossMiner

Developed using 2024.2 CSD Release



CCDC
advancing structural science

Table of Contents	
Introduction.....	2
Learning Outcomes	2
Pre-required Skills	2
Materials.....	2
Example 1. Creating a pharmacophore from a reference molecule.....	3
Conclusion	6
Example 2. Scaffold hopping using CSD-CrossMiner.....	7
Exercise.....	8
Conclusion	8
Summary	9
Next Steps.....	9
Glossary	10
CSD-CrossMiner Terminology	11
Features and Pharmacophore Representation	13

Agenda


We will make the recording available to you in the next few days.

- *Show One*: Intro and CSD and CSD-CrossMiner overview
- *Show One*: PDB overview
- *Show One*: CSD-CrossMiner explained and demonstration
- *Try One*: Hands-on example
- *Explore More*: Case-studies of CSD-CrossMiner
- *Explore More*: Quiz and Summary
- *Extra time*: More time for hands on and Q&A



CSD-CrossMiner - Strengths

- **CSD** and **PDB** databases included
 - With optional **proprietary** data
- Intuitive **pharmacophore** searching
 - Build and modify queries around key pharmacophore features.
- **Interactive** – change your hypothesis on the fly
 - See results update instantly.



donor
acceptor
planar ring
hydrophobe

Use-case: Developing novel inhibitors

Received: 10 March 2021 | Revised: 7 April 2021 | Accepted: 15 April 2021
DOI: 10.1002/jhet.4274

ARTICLE

JOURNAL OF HETEROCYCLIC CHEMISTRY WILEY

Electrocatalytic multicomponent one-pot approach to tetrahydro-2',4,4H-spiro[benzofuran-2,5'-pyrimidine] scaffold

Michail N. Elinson | Yuliya E. Ryzhkova | Anatoly N. Vereshchagin |
Fedor V. Ryzhkov | Mikhail P. Egorov

Department of Organic Chemistry, N. D. Zelinsky Institute of Organic Chemistry, Moscow, Russian Federation

Correspondence
Michail N. Elinson, Department of Organic Chemistry, N. D. Zelinsky Institute of Organic Chemistry, Leninsky Prospekt 47, 119991 Moscow, Russian Federation.
Email: elinson@ioc.ac.ru

Funding information
RFBR, Grant/Award Number: 19-29-08013

Abstract

The new electrocatalytic multicomponent transformation has been found: the electrolysis of arylaldehydes, *N,N*-dimethylbarbiturate, and cyclohexane-1,3-diones in alcohols in the presence of sodium bromide as a mediator in an undivided cell results in the formation of substituted unsymmetric spirobarbituric dihydrofurans in 62%–76% yields. The optimized reaction conditions and a mechanistic rationale for this electrocatalytic multicomponent transformation are presented. This new electrocatalytic process is a facile and efficient way to produce substituted unsymmetric spirobarbituric dihydrofurans containing both barbituric and 3,5,6,7-tetrahydro-1-benzofuran-4 (2*H*)-one fragments, which are promising compounds for different biomedical applications, among them are anticonvulsants, anti-AIDS agents, and antiinflammatory remedies. The scaffold approach was employed to find a protein, which may be influenced by the synthesized compounds—human aldose reductase was proposed. It was shown by molecular docking studies that such a scaffold search is beneficial and tetrahydro-2',4,4H-spiro[benzofuran-2,5'-pyrimidines] used in this approach are promising for the development of novel aldose reductase inhibitors.

1 | INTRODUCTION

The privileged structures or scaffolds have become one of the main trends in the pharmaceutically active compounds search [1]. Merck researchers, in study on benzodiazepines [2], introduced this definition. These privileged scaffolds usually have the rigid heterocyclic system, with special orientation of the functional substituents for target recognition.


The development of convenient and efficient way to the selective synthesis of privileged scaffolds in the one-pot multicomponent reactions is now one of the important aims of organic chemistry. Multicomponent methodology is used to ensure high efficiency and operation simplicity

with simultaneous decreasing waste formation [3]. Multicomponent or domino reactions are often used as efficient strategies in the synthesis of complex bioactive organic molecules, since they ensure multiple transformations via one-pot reaction [4]. The design and development of multicomponent reactions is until now a rapidly expanding area of research in the field of organic synthesis [5].

The organic electrochemical synthesis is a useful method with important synthetic and ecological advantages [6–8]. But, the use of electrochemical methods is often limited by equipment complexity and long reaction time.

Thus, one of the most useful electrochemical synthetic methods is the electrocatalytic transformation of



- Used a scaffold search in CSD-CrossMiner
- Searched for a target protein for spirobarbituric dihydrofuran compounds.
- Revealed two compounds that exhibited properties similar to the ones of known inhibitors of aldose reductase.



CCDC

Use-case: Exploring molecular scaffolds for a MCR library


Dr. Markella Konstantinidou et al.
EurJOC, 2020, 34: 5601-5605



MRC = Multicomponent reaction

The authors were interested in the heterocyclic ring system produced by the three component Groebke-Blackburn-Bienaymé reaction as a possible pharmaceutical scaffold.

Use-case: Catalyst ligand design



Cite this: *Catal. Sci. Technol.*, 2023,
13, 2407

High-throughput computational workflow for ligand discovery in catalysis with the CSD†

Marc A. S. Short, ^a Clare A. Tovee, ^c
Charlotte E. Willans ^b and Bao N. Nguyen ^{a,b}

A novel semi-automated, high-throughput computational workflow for ligand/catalyst discovery based on the Cambridge Structural Database is reported. Two potential transition states of the Ullmann-Goldberg reaction were identified and used as a template for a ligand search within the CSD, leading to >32 000 potential ligands. The $\Delta G^\ddagger$ for catalysts using these ligands were calculated using B97-3c//GFN2-xTB with high success rates and good correlation compared to DLPNO-CCSD(T)/def2-TZVPP. Furthermore, machine learning models were developed based on the generated data, leading to accurate predictions of $\Delta G^\ddagger$, with 70.6–81.5% of predictions falling within ± 4 kcal mol⁻¹ of the calculated $\Delta G^\ddagger$, without the need for the costly calculation of the transition state. This accuracy of machine learning models was improved to 75.4–87.8% using descriptors derived from TPSS/def2-TZVPP/GFN2-xTB calculations with a minimal increase in computational time. This new workflow offers significant advantages over currently used methods due to its faster speed and lower computational cost, coupled with excellent accuracy compared to higher-level methods.

Received 16th January 2023,
Accepted 20th March 2023

DOI: 10.1039/d3cy00083d

rsc.li/catalysis


1 Introduction

The development of organometallic catalysts, and suitable ligands, is a key challenge in the area of catalysis. While the process for traditional precious metals, such as Pd, Ru and Rh, is well established based on extensive mechanistic understanding and data-based approaches,^{1–7} ligand design for base metal catalysts is still a nascent area of research and needs to balance many more catalytic and catalyst decomposition pathways.^{8–10} Properties such as activity, selectivity and stability are the most common criteria when selecting a ligand, but solubility, toxicity and cost are also important properties to consider.¹¹ Recent applications of data science to catalysis have highlighted the computer-guided search for optimal ligands and reaction conditions as a major technology which can significantly progress this field of research.^{12,13}

While high-throughput experimental approaches have proven effective at finding suitable ligands from libraries and

optimising reaction conditions,^{14–17} these are limited by the available ligand libraries. *In silico* ligand exploration allows faster access to the entire chemical space and can lead to the discovery of unexpected ligands. In addition, new developments in high-throughput computational techniques,^{18–21} and cheminformatics tools can underpin additional filters such as ligand cost/complexity, toxicity and availability for a variety of applications in different chemical sectors.^{22–24} However, research in this field has been hampered by a lack of suitable tools for the automated exploration of ligand space, while taking into account synthetic feasibility of the ligands.^{13,25–27} In this paper, we report an alternative approach which leverages the extensive Cambridge Structural Database (CSD) and its tools to explore ligand space in a relevant catalytic reaction. This has the benefit of avoiding the synthetic feasibility challenge completely, while still maintaining a very wide chemical space coverage.

The approach was demonstrated with the copper(i)-catalysed Ullmann-Goldberg reaction, an important C–N cross-coupling reaction which has been highlighted by pharmaceutical companies as a desirable synthetic tool in the near future due to its mild conditions compared to the palladium-catalysed counterpart and sustainability credentials.²⁸ Despite this level of interest, the Pd-catalysed Buchwald-Hartwig coupling reaction is still preferred due to its reliability and better-developed ligands. Several different reaction mechanisms have been



Workflow for the identification of ligands present in the CSD and for the generation of a catalophore from a transition state reference structure.

^a School of Chemical and Process Engineering, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, UK

^b School of Chemistry, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, UK. E-mail: b.nguyen@leeds.ac.uk

^c The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ, UK. E-mail: tovee@ccdc.cam.ac.uk

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3cy00083d>

A collection of white papers

CCDC	Deposit Structures		Access Structures		Contact Us		Sign In	
	Home	Solutions	Community	Discover	Consultancy Services	Research	Support and Resources	About

White Papers

Type here to search White Papers

Tags

Access Structures
Agrochemical
AI
Aromatics Analyser
Artificial Intelligence
Automated Drug Design
British Crystallographic Association
Catalysis
CCDC
Chemical Crystallography Group
Cheminformatics
Co-crystals
Community
Computational Chemistry

Aug 6th, 2024

White Papers CSD-Discovery Drug Discovery GOLD Pharmaceuticals

White Paper: Docking Small Molecules to Nucleic Acid Targets with GOLD

Jul 31st, 2024



White Papers CSD-Discovery Docking Drug Discovery GOLD Pharmaceutical Discovery

White Paper: GOLD Study on Linear Peptide Docking

Feb 1st, 2023


White Papers CSD-CrossMiner CSD-Discovery Drug Discovery Pharmaceutical Discovery Pharmaceuticals Pharmacophore

White Paper: Identification of Novel Lead Compounds using Scaffold Hopping in CSD-CrossMiner




<https://www.ccdc.cam.ac.uk/discover/whitepapers/>

New release



- A collaboration between the CCDC, PDBe and ChEMBL.
- The release integrates structural, functional, and biochemical data.
 - Links over **235,000 CSD entries** with ChEMBL, PDBe, and other resources via UniChem.
- Accelerates research in drug discovery, drug repurposing, target validation, and understanding of drug mechanism.



What have we learnt

- ✓ An understanding of the [pharmacophore concept](#).
- ✓ [Familiarity with](#) the [CSD-CrossMiner](#) interface and how it can be used in your research.
- ✓ How to [perform pharmacophore searches](#) biologically relevant subsets of the [CSD](#) and [PDB](#).
- ✓ How to set up an [interactive pharmacophore query](#) and [save](#) the [results](#).
- ✓ How to [analyse](#) and [interact](#) with your results.

Get a certificate and help us improve

Do you want to earn a completion certificate for this session?

1. Complete the test
 2. Score 10/10
 3. Receive your certificate within a couple of hours from passing the test.
- Test available for **48h** (until Thursday at 12:15 pm GMT)!




Find the link for the test in the chat box or in our next email

How did it go today?

What do you want to learn next?

- Let us know in the polls, in the chat or via email!




If the polls do not pop-up on your screen, you can find it in the chat box. To vote, select your answer(s) and then click Submit.

CCDC

Want to explore more?

On-demand training resources



Access/Deposit Structures

CCDC for the Community

Education and Outreach

Events







Free Products

Training and Learning

Free Online Courses


Self-Guided Workshops

Training and Support Videos



CCDC

Free online training courses



With
completion
certificates!



CSDU

On-demand modules to learn how to use the CSD software at your own pace.




UWatch



UTry




UTest




Mercury




Python
API



WebCSD




GOLD
Docking



Mogul




FIMs



Particle

Coming
soon!
Cross
Miner


Visualization 101



Helping you to learn:

- The basics of **Mercury** software.
- How to **explore and pack** structures.
- How to create **high resolution images**.

GOLD Docking



Helping you to learn:


- The basics of **Hermes**.
- The basics of **protein-ligand docking**.
- Step-by-step guide on **how to use GOLD** to perform protein ligand docking.
- Where to **get started with your docking simulation**.

A collection of white papers

White Paper

CCDC
advancing structural science


Protein-Ligand Docking:
AlphaFold2-predicted vs.
X-ray Determined Protein
Structures



White Paper

CCDC
advancing structural science

**Identification of
Novel Lead Compounds
using Scaffold Hopping in
CSD-CrossMiner**



<https://www.ccdc.cam.ac.uk/discover/whitepapers/>

CCDC

Deposit Structures	Access Structures	Contact Us	Sign In
Home	Solutions	Community	Discover
		Consultancy Services	Research
		Support and Resources	About

White Papers

Type here to search White Papers

Aug 6th, 2024

White Papers CSD-Discovery Drug Discovery GOLD Pharmaceuticals

White Paper: Docking Small Molecules to Nucleic Acid Targets with GOLD

Jul 31st, 2024

White Papers CSD-Discovery Docking Drug Discovery GOLD Pharmaceutical Discovery

White Paper: GOLD Study on Linear Peptide Docking

Nov 27th, 2023

White Papers CSD-Discovery Drug Discovery GOLD Protein Prediction

White Paper: Protein-Ligand Docking, AlphaFold2-predicted vs. X-ray Determined Protein Structures

Feb 1st, 2023

White Papers CSD-CrossMiner CSD-Discovery Drug Discovery Pharmaceutical Discovery Pharmaceuticals Pharmacophore

White Paper: Identification of Novel Lead Compounds using Scaffold Hopping in CSD-CrossMiner

More learning events

CHEMAI Virtual Satellite Event

- **27th Nov** Unlocking **CSD data** for Functional Materials innovation.

CCDC Webinars

- **21st Nov** How To Use **New Semiconductor Data** in the CSD for Research and Design.

CCDC Virtual Workshops

- Coming back next year! Sign-up to our newsletter and follow us on social media.

Find all CCDC events and workshops on our website!

<https://www.ccdc.cam.ac.uk/community/events/>



CCDC